Search
forLearn
5 / 801 resultslearn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn PENTAVITIN®
learn TeraCeutic™
learn octapeptide-2
Research
5 / 27 resultsresearch NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
research Treatments for alopecia areata: a network meta-analysis
The analysis aims to identify the most effective and safest treatments for alopecia areata.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Effectiveness and Safety of Resilient Hyaluronic Acid (RHA) Dermal Fillers for the Correction of Moderate-to-Severe Nasolabial Folds in People of Color: Post Hoc Subgroup Analyses of US Pivotal Clinical Data
RHA fillers are effective and safe for treating nasolabial folds in people of color.
research The therapeutic, diagnostic, and prognostic values of extracellular vesicles (exosomes) in dermatology: A systematic review
Extracellular vesicles show potential in dermatology, but more research is needed for validation.
Community Join
5 / 1000+ resultscommunity Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community OFFICIAL Multi-Center Verteporfin Trial Recruitment
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
community Verteporfin update - donor hair regeneration human trial
A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Pyrilutamide US Phase 2 Trial?
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.